Reexamination

Subscribe to Reexamination RSS Feed

Federal Circuit Imperils Term-adjusted Patents

By Sandip H. Patel on Posted in Ex Parte, Reexamination
The Federal Circuit recently upheld the Patent Office’s decision to reject claims in four separate reexamination cases due to obviousness-type double patenting (ODP). In re Cellect, LLC, Appeal Nos. 22-1293, -1294, -1295, -1296 (Fed. Cir. Aug. 28, 2023). This decision is important because it expands ODP, a doctrine judges developed long ago, when patents received … Continue Reading

PTAB Updates and Expands the Director Review Process and Offers Transparency in Ex Parte Appeals

By Sandip H. Patel on Posted in Ex Parte, Institution / Denial, Inter Partes Review, IPR, Post Grant Review, Reexamination, Trial Procedures, Uncategorized
After the Supreme Court’s decision in United States v. Arthrex, Inc., the Patent Office implemented an interim process for the Director to review Patent Trial and Appeal Board decisions in AIA trials. The Office sought public feedback on the process last year (link) and received more than 4,000 responses (link)! The process has yet to … Continue Reading

Patent Interferences May Not Involve Pure AIA Patent

thumbnail image of DNA strandBy Sandip H. Patel on Posted in Biotechnology, Ex Parte, Interferences, Reexamination
The Patent Office is not supposed to issue separate patents for the same invention to competing inventors. Several statutory provisions empower the Office to reject pre-AIA patent application claims of the later inventor. But sometimes it’s not clear who is the later inventor. Those provisions are therefore unhelpful. So, the Patent Trial and Appeal Board … Continue Reading

Bizarre Facts Beget Bizarre Result

By Sandip H. Patel on Posted in Ex Parte, Inter Partes Review, IPR, Reexamination
Before the Federal Circuit’s recent decision in In re Vivint, Inc., Appeal 2020-1992 (Fed. Cir. Sept. 29, 2021), the Patent Trial and Appeal Board affirmed a reexamination examiner’s final rejection of Vivint’s patent claims as unpatentable over prior art. In due course, the Patent Office would have issued a certificate canceling those claims. But Vivint … Continue Reading

Does Section 285 Permit an Award of Attorney’s Fees for Patent Office Proceedings?

By Sandip H. Patel on Posted in Inter Partes Review, IPR, Reexamination, Stays
Back in 1988, the Federal Circuit reversed a district court decision that refused to award a party its reasonable attorney’s fees incurred in successfully litigating a patent’s validity before the Patent Office. PPG Indus., Inc. v. Celanese Polymer Specialties Co., 840 F.2d 1565 (Fed. Cir. 1988). The Office determined that the patent asserted in litigation—stayed … Continue Reading

USPTO to Patent Owners – Don’t Forget About Reexams and Reissues

By Heather R. Kissling on Posted in Amendments, Ex Parte, Inter Partes Review, IPR, Reexamination
Recently updated statistics from the USPTO provide little comfort for patent owners seeking to amend claims during an IPR proceeding.  The Motion to Amend Study, Installment 5 through FY2018, updated March 2019, reports that patent owners have filed a motion to amend in 326 of the 3,599 completed trials (9%) and in 90 of the … Continue Reading

Play the Claim

thumbnail image of DNA strandBy Sandip H. Patel on Posted in Biotechnology, Claim Construction, Ex Parte, Reexamination, Sections 102/103
Monsanto Technology LLC v. E.I. DuPont de Nemours & Co. Appeal 2017-1032 (Fed. Cir. Jan. 5, 2018), illustrates “[t]he life of a patent solicitor has always been a hard one.” [1] The case concerns an inter partes reexamination of a Monsanto patent in which the Patent Office concluded the claimed subject matter was inherently described in an … Continue Reading

ODP Dooms CIP

By Sandip H. Patel on Posted in Ex Parte, Reexamination
In re Janssen Biotech, Inc., Appeal 2017-1257 (Fed. Cir. Jan. 23, 2018), is a cautionary tale concerning patents protecting a blockbuster drug providing patients an important therapy and bringing its owners billions of dollars in annual revenue. It began twenty-five years ago with a then-unremarkable decision to file a patent application. The filed application was … Continue Reading
LexBlog